Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy
Authors:
Open Access
Abstract
Knowledge of clinically targetable tumor antigens is becoming vital for broader design and utility of therapeutic cancer vaccines. This information is obtained reliably by directly interrogating the MHC-I presented peptide ligands, the immunopeptidome, with state-of-the-art mass spectrometry. Our manuscript describes direct identification of novel tumor antigens for an aggressive triple-negative breast cancer model. Immunopeptidome profiling revealed 2481 unique antigens, among them a novel ERV antigen originating from an endogenous retrovirus element. The clinical benefit and tumor control potential of the identified tumor antigens and ERV antigen were studied in a preclinical model using two vaccine platforms and therapeutic settings. Prominent control of established tumors was achieved using an oncolytic adenovirus platform designed for flexible and specific tumor targeting, namely PeptiCRAd. Our study presents a pipeline integrating immunopeptidome analysis-driven antigen discovery with a therapeutic cancer vaccine platform for improved personalized oncolytic immunotherapy.Keywords
Funding Information
- H2020 European Research Council (681219)
- Jane ja Aatos Erkon Säätiö (4705796)
- HiLIFE Fellow (797011004)
- Cancer Finnish Foundation (4706116)
- Magnus Ehrnroothin Säätiö (4706235)
- Vetenskapsrådet (2015-04622)
- Stiftelsen för Strategisk Forskning (.)
- Cancerfonden (.)
- Barncancerfonden (.)
- Cancer Research Funds of Radiumhemmet (.)
This publication has 42 references indexed in Scilit:
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survivalNature Medicine, 2012
- CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancerBreast Cancer Research, 2012
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patientsJournal of Clinical Investigation, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionProceedings of the National Academy of Sciences, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infectionNature Immunology, 2008
- MHC motif viewerImmunogenetics, 2008
- The Hallmarks of CancerCell, 2000